AI-generated summary
The authors report a randomized, placebo-controlled, double-blind trial in 62 patients with allergic rhinitis treated with photobiomodulation therapy or a non-light-emitting device over one month. Compared with the control, the therapy group showed improvements in peak nasal inspiratory flow, nasal obstruction and rhinitis control scores, but no significant change in smell identification.
- Participants
- 62
- Who or what was studied
- Patients with allergic rhinitis
- Limits stated in the abstract
- The abstract reports a single trial with a modest sample of 62 patients split between two groups, and it does not state a minimum clinically important difference for the outcome scores.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on onlinelibrary.wiley.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Total energy
- 6 J, 1 J
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation therapy, Photobiomodulation, Placebo-controlled, Control group, Laser. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.